FDA Approves Risankizumab (Skyrizi) for Crohn’s Disease Uncategorized / June 17, 2022 The approval is the third indication for the anti-interleukin 23 monoclonal antibody after approval for psoriatic arthritis earlier this year and plaque psoriasis in 2019. FDA Approvals